SPIA
ALNY icon

Steward Partners Investment Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History

Steward Partners Investment Advisory’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.4K Sell
138
-1,445
-91% -$436K ﹤0.01% 3058
2026
Q1 		$524K Buy
1,583
+158
+11% +$53.8K ﹤0.01% 1502
2025
Q4 		$567K Sell
1,425
-18
-1% -$7.97K ﹤0.01% 1349
2025
Q3 		$658K Buy
1,443
+86
+6% +$35K ﹤0.01% 1246
2025
Q2 		$442K Buy
1,357
+295
+28% +$81.6K ﹤0.01% 1357
2025
Q1 		$287K Buy
1,062
+122
+13% +$31.4K ﹤0.01% 1470
2024
Q4 		$221K Buy
940
+40
+4% +$10.5K ﹤0.01% 1553
2024
Q3 		$248K Buy
900
+10
+1% +$2.6K ﹤0.01% 1419
2024
Q2 		$216K Buy
890
+175
+24% +$27.6K ﹤0.01% 1409
2024
Q1 		$107K Buy
715
+235
+49% +$39.2K ﹤0.01% 1732
2023
Q4 		$91.9K Buy
480
+60
+14% +$10.2K ﹤0.01% 1733
2023
Q3 		$74.4K Buy
420
+15
+4% +$2.86K ﹤0.01% 1721
2023
Q2 		$76.9K Hold
405
– – ﹤0.01% 1702
2023
Q1 		$81.1K Sell
405
-18
-4% -$3.78K ﹤0.01% 1665
2022
Q4 		$101K Buy
423
+18
+4% +$3.84K ﹤0.01% 1548
2022
Q3 		$81K Sell
405
-50
-11% -$9.54K ﹤0.01% 1574
2022
Q2 		$66K Sell
455
-8
-2% -$1.14K ﹤0.01% 1667
2022
Q1 		$76K Sell
463
-291
-39% -$44.3K ﹤0.01% 1709
2021
Q4 		$128K Hold
754
– – ﹤0.01% 1485
2021
Q3 		$142K Hold
754
– – ﹤0.01% 1416
2021
Q2 		$128K Sell
754
-2,521
-77% -$369K ﹤0.01% 1918
2021
Q1 		$462K Buy
3,275
+2,521
+334% +$379K 0.01% 920
2020
Q4 		$98K Sell
754
-120
-14% -$16K ﹤0.01% 1366
2020
Q3 		$127K Hold
874
– – ﹤0.01% 1124
2020
Q2 		$129K Buy
874
+24
+3% +$3.23K ﹤0.01% 1038
2020
Q1 		$92K Sell
850
-295
-26% -$34.1K ﹤0.01% 1021
2019
Q4 		$131K Hold
1,145
– – ﹤0.01% 1019
2019
Q3 		$92K Hold
1,145
– – ﹤0.01% 1116
2019
Q2 		$83K Buy
+1,145
New +$87.8K ﹤0.01% 1125
2018
Q4 		– Sell
-970
Closed -$85K – 823
2018
Q3 		$85K Buy
970
+100
+11% +$10.1K ﹤0.01% 982
2018
Q2 		$86K Sell
870
-355
-29% -$35.2K 0.01% 891
2018
Q1 		$145K Buy
+1,225
New +$158K 0.01% 687

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steward Partners Investment Advisory's ALNY Position: Q2 2026 in Review

Steward Partners Investment Advisory reduced its Alnylam Pharmaceuticals (ALNY) stake by 91% in Q2 2026, selling an estimated $436K and leaving 138 shares worth $41.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3058.

Steward Partners Investment Advisory first reported a position in ALNY in Q1 2018 and has held it in 32 quarters since. The position peaked at $658K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Steward Partners Investment Advisory held 138 shares of Alnylam Pharmaceuticals worth $41.4K as of Q2 2026.
  • Steward Partners Investment Advisory sold 1,445 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $436K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3058 holding.
  • Steward Partners Investment Advisory first reported a position in Alnylam Pharmaceuticals in Q1 2018 and has held it in 32 quarters since.
  • Steward Partners Investment Advisory's Alnylam Pharmaceuticals position peaked at $658K in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.